Advantage Alpha Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Advantage Alpha Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,623	Closed	-$227K	–	2
2025 Q3	$227K	Sell	10,623 -2,020	-16%	-$47.8K	0.07%	124
2025 Q2	$273K	Sell	12,643 -2,958	-19%	-$55K	0.07%	111
2025 Q1	$259K	Buy	15,601 +5,402	+53%	+$98.1K	0.06%	105
2024 Q4	$187K	Sell	10,199 -14,715	-59%	-$238K	0.04%	146
2024 Q3	$383K	Sell	24,914 -13,160	-35%	-$220K	0.09%	151
2024 Q2	$619K	Buy	+38,074	New	+$614K	0.14%	95

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Advantage Alpha Capital Partners's ACAD Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 10,623 shares — an estimated $227K sold.

Advantage Alpha Capital Partners first reported a position in ACAD in Q2 2024 and held it in 6 quarters. The position peaked at $619K in Q2 2024. 334 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

Advantage Alpha Capital Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Advantage Alpha Capital Partners sold 10,623 Acadia Pharmaceuticals shares in Q4 2025, an estimated $227K.
Advantage Alpha Capital Partners first reported a position in Acadia Pharmaceuticals in Q2 2024 and held it in 6 quarters.
Advantage Alpha Capital Partners's Acadia Pharmaceuticals position peaked at $619K in Q2 2024.
334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.